Register for email alerts and news feeds:
This journal | BMJ Group
rss
Drug and Therapeutics Bulletin 2005;43:1-6; doi:10.1136/dtb.2005.4311
Copyright © 2005 by the BMJ Publishing Group Ltd.

Taking stock of coxibs

Relevant BNF section: 10.1.1

Highly selective COX-2 inhibitors ('coxibs') were developed in an attempt to minimise severe gastrointestinal toxicity associated with conventional NSAIDs, without loss of anti-inflammatory efficacy. Five years ago, we concluded that the evidence then available indicated, at most, a small advantage for rofecoxib and celecoxib (the first coxibs to be marketed) over conventional NSAIDs in terms of reduced risk of severe gastrointestinal complications, such as bleeding or perforation of gastric or duodenal ulcers.1 In September 2004, newly released evidence about cardiovascular risk with rofecoxib led Merck Sharp & Dohme to voluntarily withdraw the drug worldwide.2 This has raised questions about the balance of benefit and risk with coxibs in general. Here we discuss the evidence relating to the gastrointestinal and cardiovascular safety of coxibs in patients with osteoarthritis (OA) or rheumatoid arthritis (RA).


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

This article has been cited by other articles:

  • Paton, C., Ferrier, I N. (2005). SSRIs and gastrointestinal bleeding. BMJ 331: 529-530 [Full Text]  
  • Albini, A., Noonan, D. M. (2005). Rescuing COX-2 Inhibitors From the Waste Bin. JNCI J Natl Cancer Inst 97: 859-860 [Full Text]